Premium
Genetic alterations of CCND1 and EMSY in breast cancers
Author(s) -
Kirkegaard T,
Nielsen K V,
Jensen L B,
Campbell F M,
Müller S,
Tovey S M,
Brown S,
Cooke T G,
Bartlett J M S
Publication year - 2008
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2008.03007.x
Subject(s) - cyclin d1 , gene duplication , breast cancer , cancer research , tamoxifen , fluorescence in situ hybridization , gene , cancer , biology , tissue microarray , medicine , oncology , genetics , cell cycle , chromosome
Aims: CCND1 and EMSY, on 11q13, are frequently amplified in breast cancer. CCND1 is implicated in cell cycle progression and EMSY is a BRCA2‐associated repressor protein. The aim was to investigate gene copy numbers of CCND1 and EMSY and to determine if CCND1 amplification is associated with reduced survival of tamoxifen‐treated breast cancer patients. Methods and results: Fluorescence in situ hybridization (FISH) was performed on 111 consecutive and 354 oestrogen receptor (ER)+ tamoxifen‐treated breast cancers. In the consecutive set, CCND1 and EMSY were amplified in 14.8% and 7.2%, respectively, and deleted in 8.7% and 13.5%, respectively. In the ER+ set, CCND1 and EMSY were amplified in 20.6% and 9.6%, respectively, and deleted in 1.7% and 4.2%, respectively. CCND1 and EMSY gene amplifications were associated with decreased overall survival (OS) ( P = 0.03 and P = 0.04, respectively) of patients in the ER+ set. Conclusion: As hypothesized, CCND1 amplifications are associated with poor OS in ER+ patients. EMSY amplification is also associated with poor OS. However, as >70% of EMSY amplifications were CCND1 amplified, EMSY may not have any additional effect on survival of ER+ breast cancer.